Earnings Insights · LLY · Q3 FY2026

Eli Lilly Q3 2026 Earnings: Guidance Rises as Mounjaro and Zepbound Drive $24.4B Quarter

By AlgovestIQ ResearchPublished

Share

Read Eli Lilly and Company’s results announcement (Form 8-K, filed Oct 29, 2026)

Key earnings findings

Eli Lilly and (LLY) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed

  1. Eli Lilly and reported Q3 FY2026 revenue of $24.40B against the $22.58B analyst estimate, a 8.0% beat, and EPS of $7.48 against the $5.71 analyst estimate, a 31.0% beat.
  2. Lilly raised its 2026 revenue outlook by $5.5B at the midpoint, but management also noted that roughly $2B of full-year revenue benefits from milestone payments and rebate-and-discount estimate adjustments are not expected to recur.
  3. LLY closed at $1,373.70 on Oct 29, 2026, up 6.6% from $1,288.30 on Oct 28, 2026, the last close before the results were released.

Sources: Eli Lilly and Company results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references

Did Eli Lilly and beat earnings expectations?

Actual
Estimate
Surprise
Revenue
$24.40B
$22.58B
+8.0%
EPS
$7.48
$5.71
+31.0%
  • EPS has beaten the estimate in all 8 of the most recent reported quarters on record.
  • Revenue surprise across the last 7 reported quarters has ranged from 0.5% to 11.1%.

Reported figures against analyst estimates, compiled from AlgovestIQ data.

Eli Lilly reported third-quarter revenue of $24.4B, up 39% year over year, while reported EPS rose 16% to $7.22 and non-GAAP EPS increased 7% to $7.48. Mounjaro and Zepbound remained the core growth engines, contributing more than $16B of combined quarterly revenue, while newer products in oncology, immunology and neuroscience also expanded rapidly.

The central investment question is shifting from whether Lilly can sustain high incretin demand to how durable that growth will be as realized prices decline, reimbursement expands and the product portfolio broadens. Lilly raised its 2026 revenue outlook by $5.5B at the midpoint, but management also noted that roughly $2B of full-year revenue benefits from milestone payments and rebate-and-discount estimate adjustments are not expected to recur.

Earnings Snapshot

MetricReportedChange
Revenue$24.4B+39%
U.S. revenue$15.1B+34%
Revenue outside the U.S.$9.3B+47%
Reported net income$6.5B+16%
Reported diluted EPS$7.22+16%
Non-GAAP net income$6.7B+6%
Non-GAAP diluted EPS$7.48+7%
Reported gross margin83.9%+100 bps
Non-GAAP gross margin84.4%+80 bps
R&D expense$4.2B+23%
Acquired IPR&D expense$4.2Bvs. $656M
Mounjaro revenue$10.7B+65%
Zepbound revenue$5.4B+49%
Kisunla revenue$193M+175%
Ebglyss revenue$202M+59%
Jaypirca revenue$228M+59%

The Bigger Story

Lilly’s quarterly performance again demonstrated the scale of the incretin opportunity, but it also highlighted the increasingly important role of access, pricing and geographic mix in determining the quality of that growth.

Mounjaro and Zepbound generated more than two-thirds of total revenue, with their combined sales increasing by roughly $6B from the prior-year quarter. The company is still adding patients through expanding obesity coverage, international launches and oral GLP-1 adoption. Yet price declined in both the U.S. and international markets, and part of the quarter’s revenue outperformance came from items that will not repeat.

The raised full-year outlook indicates that underlying demand has remained stronger than Lilly had anticipated at the start of the year. Management pointed to better-than-expected adoption of the Medicare GLP-1 bridge program, continued cash-pay demand outside the U.S. and international Mounjaro growth as the major drivers of the improved outlook.

Revenue and Operating Performance

Worldwide revenue increased 39% to $24.4B. Volume increased 53%, more than offsetting a 15% decline in realized prices. The quarter included approximately $900M of benefits, primarily a $410M sales-based Jardiance milestone and favorable adjustments to estimates for rebates and discounts.

Mounjaro remained the largest contributor, with sales rising 65% to $10.7B. U.S. Mounjaro revenue increased 41% to $5.0B, while international revenue increased 93% to $5.7B. International growth was primarily volume-driven, although lower realized prices, including the impact of inclusion on China’s National Reimbursement Drug List, reduced the reported revenue benefit.

Zepbound revenue increased 48% to $5.3B, entirely in the U.S. The increase reflected demand growth, partly offset by lower realized prices. Combined Mounjaro and Zepbound revenue exceeded $16B, underscoring the continued concentration of Lilly’s growth in cardiometabolic products.

The rest of Lilly’s key-product portfolio also gained traction. Key Products revenue in immunology, oncology and neuroscience doubled from a year earlier. Kisunla revenue rose 175% to $193M, Ebglyss increased 59% to $202M, and Jaypirca grew 59% to $228M. New launches also began to contribute, with Foundayo generating $184M and Inluriyo generating $73M during the quarter.

Management said Foundayo, Lilly’s oral GLP-1, is gaining adoption in obesity. More than 500,000 U.S. prescriptions were filled in the quarter, and new-patient starts doubled sequentially. About four in 10 patients starting an oral obesity medicine selected Foundayo, according to management. The product is under U.S. regulatory review for type 2 diabetes, where management sees another potential demand driver.

Profitability and Margins

Reported gross margin increased 40% to $20.5B, and gross margin improved 100 basis points to 83.9%. On a non-GAAP basis, gross margin was 84.4%, up 80 basis points. Favorable product mix and improved manufacturing costs more than offset lower realized prices.

Operating expenses rose as Lilly continued to invest behind its portfolio and launches. R&D expense increased 23% to $4.2B, reflecting investment in early- and late-stage programs as well as new molecules acquired through business development. Marketing, selling and administrative expense increased 14% to $3.1B, primarily for promotional activity supporting current and planned launches.

The quarter also carried substantial acquired in-process R&D expense. Lilly recognized $4.2B of acquired IPR&D charges, primarily related to the AtaiBeckley and Curevo acquisitions, compared with $656M in the prior-year quarter. The company said these charges reduced both reported and non-GAAP EPS by $4.57, versus $0.71 a year earlier.

As a result, EPS growth understated the operating leverage implied by revenue growth. Reported EPS rose 16% to $7.22, while non-GAAP EPS rose 7% to $7.48. The smaller non-GAAP increase partly reflects a higher non-GAAP tax rate of 24.0%, compared with 17.7% a year earlier, as well as the effect of acquired IPR&D charges included in both reported and non-GAAP EPS.

Management reported a non-GAAP performance margin of 54.2% for the quarter, up 5.9 percentage points from the prior year. The measure reflects gross margin less R&D and marketing, selling and administrative expenses as a percentage of revenue.

Demand, Customers and Pricing

Demand for Lilly’s incretin medicines remained broad-based. In the U.S., total prescriptions in the incretin market increased 32% from a year earlier. Obesity incretin prescriptions rose 82%, with Lilly accounting for approximately six of every 10 total obesity incretin prescriptions and more than seven of every 10 injectable prescriptions, according to management.

In type 2 diabetes, total U.S. incretin prescriptions rose 8%. Management said Lilly maintained more than 60% market share in that category. Outside the U.S., aggregate incretin sales rose 53% on an IQVIA gross-sales basis, while Lilly gained nearly four percentage points of share sequentially to about 58%.

The Medicare GLP-1 bridge program has become an important new access channel. Management said more than 500,000 people had filled a Lilly prescription through the program since its July launch. Roughly 80% of current bridge-program users were new to therapy or had not previously been treated, suggesting the channel is expanding the treated population rather than simply transferring patients from other channels.

Access expansion also brings mix considerations. Management expects commercial coverage to remain relatively stable in 2027, while Medicare, Medicaid and self-pay growth could represent a larger share of demand. Those channels generally carry lower net revenue per prescription, which could create a mix-related headwind even if list pricing remains disciplined.

Pricing remains the key offset to volume growth. U.S. realized prices declined 7% in the quarter, though management said the decline would have been 10% excluding favorable rebate and discount estimate adjustments. International realized prices fell 29%, largely due to Mounjaro’s reimbursement listing in China. Lilly expects net realized pricing to remain a headwind in 2027, though management expects volume growth to more than offset it.

What is Eli Lilly’s guidance for full-year 2026?

Lilly raised its full-year 2026 revenue guidance to $91B to $92B, from prior guidance of $85B to $87B.

The company also raised its non-GAAP performance-margin outlook to 52.0% to 52.5%, from 49.0% to 50.5%. Non-GAAP EPS guidance was updated to $35.00 to $36.00, compared with prior guidance of $35.50 to $36.50.

Management said the midpoint of its underlying non-GAAP EPS outlook increased by $4.07, but that improvement was more than offset by $4.57 of acquired IPR&D charges recognized during the third quarter. Guidance excludes acquired IPR&D expense incurred after September 30.

For 2027, Lilly did not provide formal financial guidance but described several expected drivers: continued incretin volume growth, the full-year effect of Medicare GLP-1 bridge access, a potential U.S. type 2 diabetes launch for Foundayo and continued international expansion. Management cautioned that 2026 revenue includes approximately $2B of non-recurring benefits, primarily milestone payments and changes in rebate and discount estimates.

Balance Sheet, Cash Flow and Capital

Lilly continued to deploy capital toward manufacturing capacity, business development and shareholder returns. The company completed the acquisition of AtaiBeckley during the quarter and completed the acquisition of Merida Biosciences after quarter-end.

It also broke ground on a $6.5B manufacturing facility in Houston and a $5B manufacturing facility in Richmond, Virginia. These investments support Lilly’s longer-term capacity plans, though they will add to capital requirements before contributing to supply.

During the quarter, Lilly paid $1.5B in dividends and repurchased $400M of shares. Net interest expense was $316M, compared with $114M in the prior-year quarter.

What Investors Should Watch

1. Incretin volume growth versus price erosion

Mounjaro and Zepbound remain the company’s principal earnings drivers. Investors should monitor whether prescription growth, expanded reimbursement and international launches continue to outweigh declining realized prices, particularly as Medicare and lower-net-price channels become a larger part of the mix.

2. Revenue quality after one-time benefits

Third-quarter revenue benefited from approximately $900M of milestones and favorable rebate and discount adjustments. Management expects about $2B of full-year 2026 benefits from similar non-recurring items. The underlying growth rate after these benefits roll off will be important for assessing the 2027 trajectory.

3. Foundayo’s obesity and diabetes launch trajectory

Foundayo is growing rapidly in the oral obesity category, but its larger opportunity may depend on a U.S. type 2 diabetes approval and subsequent reimbursement. Adoption, dose titration, persistence and its ability to expand the incretin market rather than shift patients from injectables will be key indicators.

4. Pipeline differentiation in obesity

Lilly’s obesity pipeline includes retatrutide, EloraTZP and longer-acting incretin programs. Retatrutide showed greater A1C reduction and more than double the weight loss of Ozempic 2 mg in a Phase 3 type 2 diabetes study, while EloraTZP delivered 23.3% weight loss at 48 weeks in Phase 2. The next question is whether these results can be replicated with acceptable tolerability in later-stage trials.

5. Expansion beyond cardiometabolic health

Kisunla, Ebglyss, Jaypirca and Inluriyo are growing from smaller bases. Their commercial progress, along with late-stage oncology, immunology and neuroscience programs, will determine whether Lilly can build a more diversified growth profile while incretin pricing becomes more competitive.

AlgovestIQ Takeaway

Lilly delivered another strong quarter, with 39% revenue growth and a substantial increase in full-year guidance. The core reason is clear: Mounjaro and Zepbound continue to add patients at a pace that exceeds the impact of price declines. The growth is no longer confined to U.S. cash-pay and commercial demand, with Medicare bridge adoption, international Mounjaro uptake and the early rollout of Foundayo adding new paths for expansion.

Margins also remain resilient. Gross margin improved despite lower realized prices, and the company’s non-GAAP performance margin expanded sharply as revenue growth outpaced increases in R&D and commercial spending. That operating leverage gives Lilly room to fund pipeline expansion, acquisitions and major manufacturing projects.

Still, the quality of the revenue base deserves close attention. The quarter included about $900M of favorable items, while full-year revenue includes roughly $2B of benefits that management does not expect to recur. Pricing is declining in the U.S. and more sharply internationally, especially where reimbursement broadens access. Lilly’s ability to sustain growth will increasingly depend on volume expansion rather than pricing.

The central investment issue is therefore not whether Lilly has demand today, but whether it can preserve its growth and margin profile as incretin markets mature. Evidence that Medicare access is durable, Foundayo expands treatment rather than cannibalizes injections, international growth remains broad and newer therapeutic areas become material contributors would strengthen the longer-term thesis. Faster-than-expected price erosion, weaker persistence, reimbursement disruption or growing reliance on non-recurring revenue benefits would weaken it.

How did LLY stock react?

LLY closed at $1,373.70 on Oct 29, 2026, up 6.6% from $1,288.30 on Oct 28, 2026, the last close before the results were released.

SessionCloseChange
Oct 28, 2026 (before release)$1,288.30—
Oct 29, 2026$1,373.70+6.6%
Oct 30, 2026$1,417.54+10.0%

Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.

More from this earnings season

References

  1. Management commentary, analyst questions and outlook discussed on the call. Source: Eli Lilly and Company Q3 FY2026 earnings call transcript, as of Oct 29, 2026.
  2. Reported results, segment figures and guidance from the company's results announcement. Source: Eli Lilly and Company Form 8-K, Item 2.02 (SEC EDGAR), as of Oct 29, 2026.
  3. Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Oct 29, 2026.

AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.